Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis is committed to advancing its lead drug candidate, QINPREZO (vosaroxin), through clinical trials. QINPREZO is an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer.



Type
Public
HQ
South San Francisco, US
Founded
1987
Size (employees)
37 (est)
Sunesis Pharmaceuticals was founded in 1987 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Sunesis Pharmaceuticals

Daniel Swisher

Daniel Swisher

Chief Executive Officer and President

Sunesis Pharmaceuticals Office Locations

Sunesis Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
395 Oyster Point Boulevard
Show all (1)
Report incorrect company information

Sunesis Pharmaceuticals Financials and Metrics

Sunesis Pharmaceuticals Financials

Sunesis Pharmaceuticals's revenue was reported to be $669 k in FY, 2017
USD

Revenue (Q1, 2018)

237 k

Net income (Q1, 2018)

(7.3 m)

EBIT (Q1, 2018)

(7.1 m)

Market capitalization (25-May-2018)

82.1 m

Closing share price (25-May-2018)

2.4

Cash (31-Mar-2018)

21.4 m

EV

75.3 m
Sunesis Pharmaceuticals's current market capitalization is $82.1 m.
Annual
USDFY, 2017

Revenue

669 k

General and administrative expense

13.5 m

R&D expense

21.5 m

Operating expense total

35.1 m
Quarterly
USDQ1, 2018

Revenue

237 k

General and administrative expense

3.4 m

R&D expense

4 m

Operating expense total

7.3 m
Annual
USDFY, 2017

Cash

27 m

Current Assets

32.9 m

PP&E

20 k

Total Assets

34.3 m
Quarterly
USDQ1, 2018

Cash

21.4 m

Current Assets

26.9 m

PP&E

18 k

Total Assets

27 m
Annual
USDFY, 2017

Net Income

(35.5 m)

Depreciation and Amortization

9 k

Accounts Payable

(174 k)

Cash From Operating Activities

(36.1 m)
Quarterly
USDQ1, 2018

Net Income

(7.3 m)

Depreciation and Amortization

2 k

Accounts Payable

(659 k)

Cash From Operating Activities

(6.6 m)
USDY, 2018

EV/EBIT

-10.6 x

EV/CFO

-11.5 x

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

Sunesis Pharmaceuticals News and Updates

Report incorrect company information